Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Heptagon Capital brings two Global Equity Strategies to UCITS Investors

Monday, February 24, 2014
Opalesque Industry Update - Heptagon Capital, the London-based investment management firm with $8.4bn assets under management, has just launched two new Global Equity funds on its Irish UCITS platform: the Oppenheimer Global Focus Equity Fund and the Kopernik Global All-Cap Equity Fund. This takes the number of funds on Heptagon’s $2.8bn AUM UCITS platform to five.

The Oppenheimer Global Focus Equity strategy is now available to professional UCITS investors. The strategy combines a thematic approach to idea generation with fundamental company analysis. Randall (Randy) Dishmon, the portfolio manager based in New York, started the strategy in October 2007. He looks for durable businesses, regardless of where they are located, with sustainable structural tailwinds and good economics. Entry points are critical; Randy seeks to buy when there is a large gap between market price and what the company is worth to an informed buyer. The investment horizon of 3-5 years is sufficiently long to allow real value to materialize. Although this is a high-conviction, actively-managed, benchmark-agnostic strategy (with an ‘Active Share’ of 96%), its risk profile is limited by the portfolio manager’s focus on price. Randy is an employee of OFI Global Asset Management, a wholly owned subsidiary of OppenheimerFunds, Inc.

The Oppenheimer Global Focus Equity strategy is now available to professional UCITS investors. The strategy combines a thematic approach to idea generation with fundamental company analysis. Randall (Randy) Dishmon, the portfolio manager based in New York, started the strategy in October 2007. He looks for durable businesses, regardless of where they are located, with sustainable structural tailwinds and good economics. Entry points are critical; Randy seeks to buy when there is a large gap between market price and what the company is worth to an informed buyer. The investment horizon of 3-5 years is sufficiently long to allow real value to materialize. Although this is a high-conviction, actively-managed, benchmark-agnostic strategy (with an ‘Active Share’ of 96%), its risk profile is limited by the portfolio manager’s focus on price. Randy is an employee of OFI Global Asset Management, a wholly owned subsidiary of OppenheimerFunds, Inc.

The other fund that was launched is the actively managed Kopernik Global All-Cap Equity Fund, and its investment portfolio is being managed by Dave Iben of Kopernik Global Investors, LLC in Tampa, Florida. The strategy pursues a truly global, bottom-up, research driven, fundamental evaluation approach that focusses on identifying market inefficiencies through independent analysis. Dave and his team look for undervalued and unloved stocks that will significantly reward the long term, patient investor, who truly understands a company’s business, and where more normal, stable valuations for a business will eventually be achieved.

Dave’s historical comparable strategy performance has achieved an annualised return of 9% from March 2006 to March 2012, compared to 2.8% for the MSCI All Country World Equity Index. Historically, his funds have repeatedly dominated Bloomberg Markets Rankings, having taken three of the top four spots in 2011.

The other fund that was launched is the actively managed Kopernik Global All-Cap Equity Fund, and its investment portfolio is being managed by Dave Iben of Kopernik Global Investors, LLC in Tampa, Florida. The strategy pursues a truly global, bottom-up, research driven, fundamental evaluation approach that focusses on identifying market inefficiencies through independent analysis. Dave and his team look for undervalued and unloved stocks that will significantly reward the long term, patient investor, who truly understands a company’s business, and where more normal, stable valuations for a business will eventually be achieved. Dave’s historical comparable strategy performance has achieved an annualised return of 9% from March 2006 to March 2012, compared to 2.8% for the MSCI All Country World Equity Index. Historically, his funds have repeatedly dominated Bloomberg Markets Rankings, having taken three of the top four spots in 2011.

Press release

BM

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for